AMAG Pharmaceuticals Other Current Liabilities

AMAG Pharmaceuticals (AMAG) currently reports a other current liabilities of $150M as of September 2020. That compares with $180M in the prior-year period — down 14.2% year over year. Use the charts on this page to explore AMAG Pharmaceuticals's other current liabilities history and peer comparisons.

AMAG Pharmaceuticals's other current liabilities decreased from $180M to $150M — a 14.2% year-over-year decrease (period ending September 2020). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AMAG Pharmaceuticals reported $150M in other current liabilities as of September 2020. That compares with $180M in the prior-year period — down 14.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AMAG Pharmaceuticals, and consider following AMAG for alerts when major investors trade the stock.

AMAG Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMAG with unrelated industries.